FLT3 and cancer: Ostronoff et al. analyzed a group of 253 adults and children with FLT3-ITD enrolled in five consecutive Children’s Oncology Group/Children’s Cancer Group and SWOG trials, and observed a 3-year OS of 45% and EFS of 30% [20].